163 related articles for article (PubMed ID: 37896797)
1. Viral Entry Inhibitors Protect against SARS-CoV-2-Induced Neurite Shortening in Differentiated SH-SY5Y Cells.
Mignolet M; Gilloteaux J; Halloin N; Gueibe M; Willemart K; De Swert K; Bielarz V; Suain V; Pastushenko I; Gillet NA; Nicaise C
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896797
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of neuroblastoma and glioblastoma cell lines to SARS-CoV-2 infection.
Bielarz V; Willemart K; Avalosse N; De Swert K; Lotfi R; Lejeune N; Poulain F; Ninanne N; Gilloteaux J; Gillet N; Nicaise C
Brain Res; 2021 May; 1758():147344. PubMed ID: 33556379
[TBL] [Abstract][Full Text] [Related]
3. Comparison of SARS-CoV-2 Receptors Expression in Primary Endothelial Cells and Retinoic Acid-Differentiated Human Neuronal Cells.
Benedetti F; Silvestri G; Mavian C; Weichseldorfer M; Munawwar A; Cash MN; Dulcey M; Vittor AY; Ciccozzi M; Salemi M; Latinovic OS; Zella D
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834998
[TBL] [Abstract][Full Text] [Related]
4. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
5. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
[TBL] [Abstract][Full Text] [Related]
7. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
8. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions.
Lin H; Cherukupalli S; Feng D; Gao S; Kang D; Zhan P; Liu X
Curr Med Chem; 2022; 29(4):682-699. PubMed ID: 33881969
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
11. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
[TBL] [Abstract][Full Text] [Related]
12. An improved Fuzzy based GWO algorithm for predicting the potential host receptor of COVID-19 infection.
Achom A; Das R; Pakray P
Comput Biol Med; 2022 Dec; 151(Pt A):106050. PubMed ID: 36334362
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
Verma D; Church TM; Swaminathan S
J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
Rowland R; Brandariz-Nuñez A
Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
19. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression.
Bartolomeo CS; Lemes RMR; Morais RL; Pereria GC; Nunes TA; Costa AJ; de Barros Maciel RM; Braconi CT; Maricato JT; Janini LMR; Okuda LH; Lee KS; Prado CM; Ureshino RP; Stilhano RS
Life Sci; 2022 Nov; 308():120930. PubMed ID: 36075471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
